These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Clinical Outcome
22 results:

  • 1. clinical and Biologic Correlates of ADORA2A Transcriptomic Expression in cancer.
    Shreenivas A; Nishizaki D; Lee S; Pabla S; Nesline M; Conroy JM; DePietro P; Kato S; Kurzrock R
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731962
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Complete remission in a pretreated, microsatellite-stable,
    He L; Li H; Wang Y; Li W; Gao L; Xu B; Hu J; He P; Pu W; Sun G; Wang Z; Han Q; Liu B; Chen H
    Front Immunol; 2024; 15():1354613. PubMed ID: 38617840
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. N6-methyladenosine reader protein IGF2BP1 suppresses CD8 + T cells-mediated tumor cytotoxicity and apoptosis in colon cancer.
    Peng Y; Zhang Z; Yang G; Dai Z; Cai X; Liu Z; Yun Q; Xu L
    Apoptosis; 2024 Apr; 29(3-4):331-343. PubMed ID: 37848671
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Immune Marker Spatial Distribution and clinical outcome after pd-1 Blockade in Mismatch Repair-deficient, Advanced colorectal Carcinomas.
    Saberzadeh-Ardestani B; Graham RP; McMahon S; Ahanonu E; Shi Q; Williams C; Hubbard A; Zhang W; Muranyi A; Yan D; Jin Z; Shanmugam K; Sinicrope FA
    Clin Cancer Res; 2023 Oct; 29(20):4268-4277. PubMed ID: 37566222
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity.
    Li Y; Shen Z; Chai Z; Zhan Y; Zhang Y; Liu Z; Liu Y; Li Z; Lin M; Zhang Z; Liu W; Guan S; Zhang J; Qian J; Ding Y; Li G; Fang Y; Deng H
    Gut; 2023 Nov; 72(12):2307-2320. PubMed ID: 37507218
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Spatially resolved multimarker evaluation of CD274 (PD-L1)/pdcd1 (pd-1) immune checkpoint expression and macrophage polarisation in colorectal cancer.
    Elomaa H; Ahtiainen M; Väyrynen SA; Ogino S; Nowak JA; Lau MC; Helminen O; Wirta EV; Seppälä TT; Böhm J; Mecklin JP; Kuopio T; Väyrynen JP
    Br J Cancer; 2023 Jun; 128(11):2104-2115. PubMed ID: 37002343
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Combined pd-1, BRAF and MEK inhibition in BRAF
    Tian J; Chen JH; Chao SX; Pelka K; Giannakis M; Hess J; Burke K; Jorgji V; Sindurakar P; Braverman J; Mehta A; Oka T; Huang M; Lieb D; Spurrell M; Allen JN; Abrams TA; Clark JW; Enzinger AC; Enzinger PC; Klempner SJ; McCleary NJ; Meyerhardt JA; Ryan DP; Yurgelun MB; Kanter K; Van Seventer EE; Baiev I; Chi G; Jarnagin J; Bradford WB; Wong E; Michel AG; Fetter IJ; Siravegna G; Gemma AJ; Sharpe A; Demehri S; Leary R; Campbell CD; Yilmaz O; Getz GA; Parikh AR; Hacohen N; Corcoran RB
    Nat Med; 2023 Feb; 29(2):458-466. PubMed ID: 36702949
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. A novel prognostic immunoscore based on The cancer Genome Atlas to predict overall survival in colorectal cancer patients.
    Tang Z; Wu Y; Sun D; Xue X; Qin L
    Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34608935
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Impact of PD-L1 and pd-1 Expression on the Prognostic Significance of CD8
    Munari E; Marconi M; Querzoli G; Lunardi G; Bertoglio P; Ciompi F; Tosadori A; Eccher A; Tumino N; Quatrini L; Vacca P; Rossi G; Cavazza A; Martignoni G; Brunelli M; Netto GJ; Moretta L; Zamboni G; Bogina G
    Front Immunol; 2021; 12():680973. PubMed ID: 34122444
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Removal of N-Linked Glycosylation Enhances PD-L1 Detection in Colon cancer: Validation Research Based on Immunohistochemistry Analysis.
    Xu J; Yang X; Mao Y; Mei J; Wang H; Ding J; Hua D
    Technol Cancer Res Treat; 2021; 20():15330338211019442. PubMed ID: 34060360
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Identification of Immune-Related LncRNA Pairs for Predicting Prognosis and Immunotherapeutic Response in Head and Neck Squamous Cell Carcinoma.
    Wang X; Cao K; Guo E; Mao X; Guo L; Zhang C; Guo J; Wang G; Yang X; Sun J; Miao S
    Front Immunol; 2021; 12():658631. PubMed ID: 33995377
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Microsatellite instability status differentially associates with intratumoral immune microenvironment in human cancers.
    Zhang P; Liu M; Cui Y; Zheng P; Liu Y
    Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32823273
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. The Latest Findings of pd-1/PD-L1 Inhibitor Application in Gynecologic cancers.
    Kooshkaki O; Derakhshani A; Safarpour H; Najafi S; Vahedi P; Brunetti O; Torabi M; Lotfinejad P; Paradiso AV; Racanelli V; Silvestris N; Baradaran B
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708748
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer.
    Kitsou M; Ayiomamitis GD; Zaravinos A
    Int J Oncol; 2020 Jul; 57(1):237-248. PubMed ID: 32468013
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Toxicity associated with pd-1 blockade after allogeneic haematopoietic cell transplantation.
    Ortega Sanchez G; Stenner F; Dirnhofer S; Passweg J; Gerull S; Halter JP; Zippelius A; Läubli H
    Swiss Med Wkly; 2019 Nov; 149():w20150. PubMed ID: 31707719
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of pd-1/PD-L1 checkpoint blockade.
    Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
    Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. CD8
    E J; Yan F; Kang Z; Zhu L; Xing J; Yu E
    Hum Immunol; 2018 Jun; 79(6):446-452. PubMed ID: 29544815
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Results and challenges of immune checkpoint inhibitors in colorectal cancer.
    Emambux S; Tachon G; Junca A; Tougeron D
    Expert Opin Biol Ther; 2018 May; 18(5):561-573. PubMed ID: 29471676
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Cytosolic high-mobility group box protein 1 (HMGB1) and/or pd-1+ TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy.
    Huang CY; Chiang SF; Ke TW; Chen TW; Lan YC; You YS; Shiau AC; Chen WT; Chao KSC
    Cancer Immunol Immunother; 2018 Apr; 67(4):551-562. PubMed ID: 29270668
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy.
    Rödel F; Steinhäuser K; Kreis NN; Friemel A; Martin D; Wieland U; Rave-Fränk M; Balermpas P; Fokas E; Louwen F; Rödel C; Yuan J
    Radiother Oncol; 2018 Feb; 126(2):214-221. PubMed ID: 29122359
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.